Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biolase gets access to wider market in the US:

This article was originally published in Clinica

Executive Summary

In a move that expands the market for its products Biolase Technology has received US FDA approval to sell its LaserSmile dental laser as a treatment for periodontal disease. Previously cleared for just cosmetic and soft-tissue applications, the device can now be used to treat both early and advanced stages of periodontal disease, which the firm claims is a US first for a 810nm solid-state laser. More than 30% of adults over 50 years of age suffer from periodontal disease, said the San Clemente, California firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel